{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-377059","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2026-08-31T21:18:23+00:00","discovered_at":"2026-08-31T21:20:00.508177+00:00","generated_at":"2026-08-31T21:20:09.908205+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kyntra Bio cuts royalty financing cap from $125M to $65M; pays $42.6M upfront","bullets":["Max payments under royalty financing cut from $125M to $65M; $42.6M accelerated payment brings total paid to $50M, full return of investor capital.","Remaining $15M cap paid from 50% of Astellas EVRENZO revenue (ex-Japan); after cap, Kyntra retains all royalties.","FibroGen Europe bankruptcy settled for ~$0.1M vs $19.2M obligations; combined liability reduction ~$80M.","Pro forma cash $53.1M as of June 30, 2026; cash runway into Q4 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-377059","json":"https://secwatch.observer/filing/0001193125-26-377059.json","markdown":"https://secwatch.observer/filing/0001193125-26-377059.md","text":"https://secwatch.observer/filing/0001193125-26-377059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000119312526377059/0001193125-26-377059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000119312526377059/kynb-20260831.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-31T21:20:09.908205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}